Document:

Exhibit 10.35

 

UNIQURE B.V.

 

Meibergdreef 61
 Amsterdam 1105 BA, The Netherlands

 

January 17, 2014

 

Dr. David Schaffer 
 Dr. David Kirn 
 4D Molecular Therapeutics, LLC
 19 Rima Court
 Danville, CA 94526

 

Re:                             Commitment Letter Pursuant to Collaboration and License Agreement

 

Gentlemen:

 

We refer to (1) the Collaboration and License Agreement by and between 4D Molecular Therapeutics, LLC (“4DMT”) and uniQure Biopharma B.V. dated as of the date hereof (the “CLA”), and (2) the Grant Letters by and between uniQure B.V. and each of you dated as of the date hereof (the “Option Grants”). This letter is the Commitment Letter referred to in the Introduction to the CLA.

 

We hereby agree as follows:

 

1.             Supervisory Board Membership.  We hereby undertake to procure that Dr. Schaffer is appointed as a member of the Supervisory Board of uniQure B.V. (the “Supervisory Board”) for a two-year term, commencing immediately following an extraordinary meeting of the shareholders of uniQure B.V. to be convened within 15 days of the date hereof(the “Initial Term”). At the expiration of such Initial Term, we agree that a person nominated by 4DMT shall be nominated by the Supervisory Board for election to a further three-year term as a member of the Supervisory Board, subject to approval by the shareholders of uniQure B.V. In the event that the CLA is terminated pursuant to Section 10.2 thereof prior to the expiration of the Initial Term or any subsequent term of office, Dr. Schaffer (or such other person as may be nominated by 4DMT from time to time) hereby agrees that he shall be deemed to have resigned his position as a member of the Supervisory Board effective immediately upon such termination of the CLA.

 

2.             Supervisory Board Observer Rights. We hereby agree that Dr. Kirn shall have a right to attend all meetings of the Supervisory Board in a nonvoting observer capacity; provided, however, that Dr. Kirn agrees to hold in confidence all information provided; and provided further, that we reserve the right to withhold any information and to exclude Dr. Kirn from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between uniQure B.V. and its counsel or result in disclosure of trade secrets or a conflict of interest. The right provided by this paragraph 2 shall terminate on the first anniversary hereof.

 

1

 

3.             Advisory Board Memberships. We hereby undertake to form a Scientific Advisory Board and a Clinical Advisory Board by no later than the first anniversary hereof. Upon the formation of each such committee, we undertake to appoint one nominee of 4DMT as a member of each such committee, such membership to continue during the Research Term (as defined in the CLA). The initial 4DMT nominee to the Scientific Advisory Board shall be Dr. Schaffer and the initial 4DMT nominee to the Clinical Advisory Board shall be Dr. Kirn.

 

The following sections of the CLA are hereby incorporated by reference herein and shall govern this letter:  Article XI (Dispute Resolution); Section 12.1 (Governing Law); Section 12.2 (Waiver); Section 12.3 (Notices); Section 12.6 (Severability); Section 12.7 (Assignment); Section 12.8 (Counterparts); and Section 12.9 (Force Majeure).

 

*****

 

2

 

	
Very truly yours,
    	
 
    
	
 
    	
 
    
	
UNIQURE B.V.
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/ Jörn Aldag
    	
 
    
	
Name:
    	
Jörn Aldag
    	
 
    
	
Title:
    	
Chief Executive   Officer
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
ACKNOWLEDGED AND   AGREED:
    	
 
    
	
 
    	
 
    
	
4D MOLECULAR   THERAPEUTICS, LLC
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/ Jörn Aldag
    	
 
    
	
Name:
    	
Jörn Aldag
    	
 
    
	
Title:
    	
Chief Executive   Officer
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
/s/ David Schaffer
    	
 
    
	
DR. DAVID SCHAFFER
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
/s/ David Kirn
    	
 
    
	
DR. DAVID KIRN
    	
 
    
					

 

3Naked Brand Group Inc. - Exhibit 10.1 - Filed by newsfilecorp.com

FOR VALUE RECEIVED, Naked Brand Group Inc., a Nevada
corporation (the “Borrower), promises to pay to Alan Aaron or its Assignees (the
“Lender”) the Principal Sum along with the Interest Rate and any other fees
according to the terms herein. This Note will become effective only upon
execution by both parties and delivery of the first payment of Consideration by
the Lender (the “Effective Date”).

The consideration is $250,000 (two hundred and fifty thousand)
payable by wire which shall be paid by the Lender upon closing of this Note.

1. Principal Sum. The principal sum is
$309,062.50 (three hundred nine thousand and sixty two) (the “Principal
Sum”). The Principal Sum is comprised of: (i) the principal balance of
$250,000 (the “Principal Balance”); (ii) a one-time interest charge of
15% or $37,500 (the “OID”); and (iii) an amount of $21,562.50, being the
remaining principal balance due on the promissory note dated September 4, 2013
between the Borrower and the Lender (the “First Note”). 

2. Maturity. The maturity date is 6 (six) months
from the Effective Date (the “Maturity Date”) and is the date upon which
the Principal Sum of this Note shall be due and payable. 

3. Repayment. The Borrower may repay this Note at
any time on or before the Maturity Date without penalty. Principal repayments
are due as outlined in the Payment Schedule (Exhibit A) during the term of the
Note. The OID of $37,500 and the remaining balance due in connection with the
First Note of $21,562.50 will be repayable on the Maturity Date, as outlined in
the Payment Schedule.

4. Conversion. The OID may be converted on the
Maturity Date, at the option of the Lender, into shares of common stock of the
Borrower at a conversion price of $0.10 per share by delivering to the Borrower
of a completed notice of conversion in the form attached hereto as Exhibit D
(the “Conversion Notice”) on the Maturity Date. 

The delivery of the Conversion Notice duly executed by the
Lender shall be deemed to constitute a contract between the Lender and the
Borrower whereby (i) the Lender subscribes for the number of shares to which the
Lender shall be entitled to receive upon such conversion, (ii) the Lender
releases, upon receipt of the shares issued in respect of the conversion, the
Borrower from all liability thereon or from all liability with respect to the
OID converted, and (iii) the Borrower agrees that the surrender of the OID for
conversion constitutes full payment of the subscription price for the shares
issuable on such conversion and that such shares will be issued as fully paid
and non-assessable shares of the Borrower. 

Notwithstanding anything herein contained, the Borrower shall
in no case be required to issue fractional shares or to pay any cash adjustment
in lieu of any fractional share upon the conversion of this Note. Any fractions
will be rounded to the nearest whole number with fractions of one-half or
greater being rounded to the next higher whole number and fractions of less than
one-half being rounded to the next lower whole number. 

5. Default. The following are events of default
under this Note: (i) Borrower shall fail to pay any principal sum or payment
under the Note when due and payable, and does not cure such failure by paying
any such amounts due and payable within 10 days of such due date; or (ii) the
Borrower generally fails to pay, or admits in writing its inability to pay, its
debts as they become due, subject to applicable grace periods, if any; or (iii)
the Borrower shall make a general assignment for the benefit of its creditors;
or (iv) the Borrower shall file a petition for relief under any bankruptcy,
insolvency, or similar law (domestic or foreign); or (v) an involuntary
proceeding shall be commenced or filed against the Borrower. 

6. Remedies. In the event of default, the
outstanding principal amount of this Note and any other amounts owing in respect
thereof shall become, at the Lender’s election, immediately due and payable in
cash at the Mandatory Default Amount. The Mandatory Default Amount consists of
(i) the remaining Principal Sum outstanding under the Note; and (ii)
reimbursement of reasonable attorney’s fee and costs.

7 Security. The Principal Sum due under this Note
will be unsecured. 

8. Assignability. The Borrower shall not assign
this Note. This Note will be binding upon the Borrower and its successors and
will accrue to the benefit of the Lender and may be assigned by the Lender to
anyone of its choosing without the Borrower’s approval. 

9. Governing Law. This Note will be
governed by, and enforced in accordance with the laws of the state of New York.

10. Extinguishment of First Note. The Lender
acknowledges that the remaining principal balance due under the First Note will
be repaid as consideration for the Principal Sum due under the Note.

 

DATED this 13th day of January 2014 

Borrower: 

	
      /s/Joel Primus 

       
	 
	Joel Primus 	 
	Naked Brand Group Inc. 	 
	Chief Executive Officer 	 

Date: January 13, 2014 

Lender: 

	
      /s/Alan Aaron 

       
	 
	Alan Aaron 	 
	 	 
	Date: January 13, 2014 	 

Exhibit A 

	Date 	Principal 	Interest 	Total Payment 
	February 13, 2014 	$ 41,666.67 	Nil 	$ 41,666.67 
	March 13, 2014 	$ 41,666.67 	Nil 	$ 41,666.67 
	April 13, 2014 	$ 41,666.67 	Nil 	$ 41,666.67 
	May 13, 2014 	$ 41,666.67 	Nil 	$ 41,666.67 
	June 13, 2014 	$ 41,666.67 	Nil 	$ 41,666.67 
	July 13, 2014 	$ 63,229.15 	$ 37,500.00 	$ 100,729.15 
	Total payments 	$ 271,562.50 	$ 37,500.00 	$ 309,062.50

EXHIBIT D 

FORM OF CONVERSION NOTICE

TO:   NAKED BRAND GROUP INC. (the
“Corporation”) 

          The
undersigned, being the Lender defined in the Promissory Note dated January 13,
2014 granted by the Corporation (the “Note”) hereby
subscribes for shares of the Corporation, on the terms specified in the Note, to
the extent of $21,562.50 of the OID. The Note is hereby tendered to the
Corporation and will, upon due issuance of the Shares aforesaid and, if
required, any replacement Note for any portion of the Note not converted, be
null and void. 

          The
Shares subscribed for will be issued as set forth below and will be mailed or
delivered to the address set forth below. 

          Capitalized
terms not defined on this Conversion Notice have the meanings ascribed to them
in the Note. 

          DATED
this                          day
of                                         ,
20      . 

	 	By: 	 
	 	 	 
	 	Name: 	 
	 	 	 
	 	Title: 	 

Print below the name and address in full of the Lender in whose
name the Shares subscribed for are to be issued.

	Name: 	 
	Address: 

	 
	Tax ID, if 
applicable:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]